别名 DISSEMINATED LUPUS ERYTHEMATOSUS、Disseminated lupus erythematosus、LE SYNDROME + [73] |
简介 A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. |
靶点 |
作用机制 C5抑制剂 |
在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 中国 |
首次获批日期2024-02-06 |
靶点 |
作用机制 CFB抑制剂 |
在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2023-12-05 |
靶点 |
作用机制 C5抑制剂 |
最高研发阶段批准上市 |
首次获批国家/地区 日本 |
首次获批日期2023-09-25 |
开始日期2026-01-15 |
开始日期2025-01-01 |
开始日期2025-01-01 |
申办/合作机构 |